Stock Events

Stock Events

Search...

Amicus Therapeutics

€10.9

39

+€0+0% Today

Statistics

Day High

10.9

Day Low

10.9

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

3.44B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

5NovExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-0.18

-0.12

-0.06

0

Expected EPS

0.000165

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AM6.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Amicus Therapeutics' focus on rare and orphan diseases.

Biogen competes in the biotechnology space, particularly in developing therapies for neurological and neurodegenerative diseases, overlapping with some of Amicus' therapeutic areas.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapies for genetic diseases, directly competing with Amicus' gene therapy approaches for similar conditions.

Biomarin Pharmaceutical

BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, closely competing with Amicus Therapeutics' product portfolio.

Sarepta Therapeutics

Sarepta Therapeutics specializes in precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, competing with Amicus' focus on rare genetic disorders.

bluebird bio focuses on gene therapies for genetic diseases and cancer, competing with Amicus Therapeutics in the gene therapy space for rare diseases.

CRISPR Therapeutics

CRISPR Therapeutics is involved in gene editing for genetic diseases, which competes with Amicus' efforts in developing therapies for rare genetic conditions.

Novartis AG, through its advanced therapy platforms, competes in the same space as Amicus, particularly in gene therapies and treatments for rare diseases.

Pfizer has a growing interest in rare diseases and gene therapy, making it a competitor as it expands its portfolio in areas that overlap with Amicus Therapeutics' focus.

Analyst Ratings

17.13€Average Price Target

The highest estimate is €20.

From 9 ratings within the last 6 months. This is not an investment recommendation.

Buy

89%

Hold

11%

Sell

0%

About

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Show more...

CEO

Mr. Bradley L. Campbell M.B.A.

Employees

500

Country

US

ISIN

US03152W1099

WKN

000A0MSMZ

Listings